The phosphatidylinositol 3-kinase (PI3K) regulatory subunits p55a and p50a are coordinately transcriptionally upregulated by signal transducer and activator of transcription 3 (Stat3) at the onset of mammary gland involution, a process that requires Stat3. Deletion of both p55a and p50a subunits in vivo abrogated mammary epithelial cell death during involution. This was associated also with reduced cytosolic levels and activity of the cysteine protease cathepsin L, which is implicated in lysosomal-mediated programmed cell death (LM-PCD) and is upregulated in involution. Furthermore, involution is delayed in cathepsin L-deficient mice suggesting that the p55a/p50a subunits mediate cell death in part by elevating the level of cathepsin L resulting in increased cytosolic activity. Surprisingly, we found that p55a/p50a localize to the nucleus where they bind to chromatin and regulate transcription of a subset of inflammatory/acute phase genes that are also Stat3 targets. Our findings reveal a novel role for these PI3K regulatory subunits as regulators of LM-PCD in vivo. Cell Death and Differentiation (2014) 21, 1442-1450; doi:10.1038/cdd.2014.59; published online 6 June 2014
The class IA phosphatidylinositol 3-kinases (PI3Ks) are heterodimeric enzymes that comprise a p110 catalytic subunit (p110a, p110b or p110d) and a regulatory subunit (p85a, p85b, p55a, p55g or p50a). 1 A single gene, pik3r1, encodes p85a, p55a and p50a and all three subunits share a common carboxy-terminal domain, which encompasses the p110 subunit binding site, a proline-rich region and two Src homology 2 (SH2) domains, which bind to a plethora of proteins including receptor tyrosine kinases and ankyrin3. 2 The unique amino terminal sequence of p85a comprises a Src homology 3 (SH3) and a breakpoint cluster region-homology domain, which bind to the negative regulator of PI3K, phosphatase and tensin homolog enhancing its lipid phosphatase activity. 3 The p85a subunit binds also to Rab5 and other proteins including dynamin and Grb2, 2 and can interact with X-box-binding protein-1 (XBP-1), a transcriptional mediator of the unfolded protein response (UPR), to enhance nuclear accumulation of XBP-1s in an endoplasmic reticulum (ER) stress-dependent manner. 4, 5 The p55a and p50a subunits have much smaller unique N-terminal sequences of 34aa for p55a and 6aa for p50a. Specific ablation of these subunits by deleting exons 1B (p50a) and 1C (p55a) results in improved insulin sensitivity and protection from obesityinduced insulin resistance. 6 However, although p55a has been shown to bind to tubulin, 7 the function of these subunits is still somewhat enigmatic.
Involution can be divided into two phases, the first of which is reversible. 8 In the mouse, this reversible phase persists for approximately 48 h and thereafter tissue remodeling occurs, precluding re-initiation of lactation. Gene expression analyses revealed an unexpected role for inflammatory regulators and the acute phase response (APR) during involution, reflecting the extensive tissue remodeling that occurs simultaneously with epithelial cell death. [9] [10] [11] We have shown previously that cell death during first phase involution is mediated by signal transducer and activator of transcription 3 (Stat3) regulated lysosomal membrane permeabilization and is independent of executioner caspases. 12 Furthermore, the lysosomal cathepsins B and L are strikingly upregulated during involution in a Stat3-dependent manner and leak from lysosomes to initiate cell death. Thus, Stat3 is a master regulator of the involution process.
We demonstrated previously that transcription of p55a and p50a is specifically and markedly upregulated by Stat3 at the onset of involution 13 and in a mammary epithelial cell line; 14 and this prompted us to investigate their role in mediating the Stat3 signal during the involution process. Using mice in which the unique exons encoding the amino-termini of p55a and p50a were deleted, we found that mammary gland development occurred normally until involution, when cell death was markedly reduced. The cysteine protease cathepsin L, which is implicated in lysosomal-mediated programmed cell death (LM-PCD), is rapidly upregulated in involution, although reduced cytosolic levels and activity are found in p55a À / À / p50a À / À glands. Furthermore, cathepsin L-deficient mice exhibited delayed involution suggesting that the p55a/p50a subunits mediate cell death in part by elevating cathepsin L activity. Interestingly, p55a/p50a localize to the nuclei of involuting epithelial cells and regulate transcription of a number of genes including some Stat3 target genes.
Results
p55a/p50a regulate cell death in vivo. Examination of mammary glands from mice deficient in both p55a and p50a, but replete for p85a, revealed a striking delay in involution (Figures 1a and b) . This was associated with delayed tissue remodeling, as shown by the quantification of the area occupied by adipocytes, which is significantly reduced at 48 and 72 h of involution (Figure 1c ). In addition, 24-h involution samples show a 12-fold reduction in the number of detached dying cells (Figures 1b and d) , also indicated by decreased cleaved caspase 3 levels (Figures 1e and f) . Levels of p-Akt and phospho-glycogen synthase kinase 3 b were similar between control and knockout mice except at 72-h involution (Supplementary Figure 1a) due largely to the presence of Akt2 in the adipose tissue at this time point ( Supplementary  Figures 1b and c) . Thus, the role of p55a/p50a during involution is likely independent of PI3K catalytic activity. This suggests that these subunits have a role in regulating cell death during involution by some other mechanism. Notably, p55a/p50a expression in the mammary gland seems to be restricted to the epithelium and is not found in the adipose compartment (Supplementary Figure 1c) . p55a/p50a regulate cathepsin L expression and cytosolic activity. We have shown previously that, during involution, Stat3 upregulates expression of the lysosomal proteases cathepsins B and L while downregulating expression of the endogenous cathepsin inhibitor Spi2a. 12 Importantly, as opposed to cathepsin B, which shows a modest 4-fold increase at the onset of involution (Kreuzaler et al. 12 and Figure 3d ), cathepsin L shows a striking induction within 24-h involution, as shown by immunofluorescence staining and a corresponding 22-fold induction at the mRNA level (Figures 2a  and 3d ; Kreuzaler et al. 12 and Burke et al.
15
). We confirmed that cathepsin L localizes to vesicles at 24-h involution using immunofluorescence microscopy ( Figure 2a ). The discrete puncta observed become more diffuse as involution progresses and begin to disappear altogether at 96 h, reflecting the reduction in cathepsin L compared with cathepsin B at this time point. 12 Interestingly we found that, while both cathepsins B and L normally colocalized, a proportion of the cathepsin L-positive vesicles did not contain cathepsin B (Figure 2b and Supplementary Figure 2) suggesting that there may be an alternative transport system that delivers cathepsin L to discrete vesicles. Importantly, ablation of p55a/p50a affected primarily cathepsin L levels, which were markedly reduced in knockout tissue and this was particularly marked in the extent of cathepsin L leakage to the cytosol (Figure 2c and Supplementary Figure 3a) . In contrast, cathepsin B levels were relatively unchanged ( Supplementary Figures 3b-d) . This was reflected in enzymatic activity assays on both lysosomal and cytosolic extracts, showing reduced cathepsin L cytosolic activity both at 24-and 48-h involution ( Figure 2d ). As cathepsin B activity is unaffected by p55a/p50a ablation, this suggests that lysosomal leakiness is unlikely to be perturbed. Therefore, the reduced cytosolic activity of cathepsin L most likely reflects the reduced protein levels observed.
We have previously shown that the mitochondrial pathway of cell death is downstream of LM-PCD and is executioner caspase independent. 12 Nevertheless, we investigated whether deletion of p55a/p50a affected components of the mitochondrial pathway. Thus, we analyzed the expression of the pro-apoptotic Bcl-2 family members Bax and Bid and the anti-apoptotic factors Bcl-2 and Bcl-xL (Supplementary Figure 4a) . No major changes were observed, although slightly reduced cytosolic levels of cytochrome c were apparent at 48-h involution in the p55a À / À /p50a À / À glands ( Supplementary Figure 4b) , suggesting an impact of cathepsin L on the mitochondria. p55a/p50a regulate gene expression at the transcriptional and post-transcriptional level. Recently, p85a has been shown to interact with XBP-1 and regulate its nuclear translocation and transcriptional activity. 4, 5 We therefore sought to determine if p55a/p50a could exert a similar function on the master regulator of involution, Stat3. Analysis of total and nuclear extracts of p55a À / À /p50a À / À glands at different involution time points revealed no difference in the induction of Stat3 phosphorylation or on its translocation to the nucleus (Supplementary Figures 5a-c) . Nuclear localization of p85a and p85b has been described in different cellular systems. 4, 16, 17 To determine if the regulatory subunits localize to the nuclei of mammary cells, we analyzed nuclear and cytosolic extracts of a number of involution time points. Interestingly, we detected nuclear p85a at 10 days lactation, while p55a and p50a exhibited nuclear localization immediately upon their expression at the onset of involution (Figure 3a ). Further analysis of nuclear compartments revealed an association of all three regulatory subunits, and phospho-Stat3 (p-Stat3), with chromatin-enriched extracts of EpH4 mammary epithelial cells, suggesting either a direct or indirect role in regulating transcription ( Figure 3b ). This prompted us to carry out a microarray analysis of control and p55a À / À /p50a À / À mammary glands at 24 h of involution. A number of genes were either upregulated or downregulated in the p55a À / À /p50a À / À glands (Supplementary  Tables 1 and 2 , respectively) and a subset of these was validated by QRT-PCR (Figure 3c ). Interestingly, a number of these genes are associated with cell migration and tissue remodeling and the APR. Although osteopontin (Spp1), SAA2 and Tlr2 are expressed at higher levels in the absence of p55a/p50a, Slpi and synaptopodin are suppressed in p55a/p50a-deficient glands. Many of the genes identified in the microarray have previously been shown to be Stat3 targets (Hughes et al., 10 Supplementary Table 3 and CJW, unpublished). This suggests that the regulatory subunits may fine tune Stat3-regulated gene expression. However, transcription of Stat3-regulated genes implicated in LM-PCD, such as Spi2a and cathepsins B and L, was not affected by ablation of p55a/p50a although there was a trend of reduced expression of cathepsin L (Figure 3d ). Taken together, these data suggest that p55a/p50a modulate the expression of distinct sets of genes at either the transcriptional or post-transcriptional level during mammary gland involution. Cathepsin L is an important mediator of mammary gland involution. The specific regulation of cathepsin L downstream of the small regulatory subunits p55a/p50a points to an important role for this lysosomal enzyme in cell death. To address this function directly, we investigated involution at various time points in cathepsin L null mice. Involution was markedly delayed with a threefold reduction in the extent of tissue remodeling observed in ctsl À / À mammary glands at 72-h involution as measured by the area occupied by adipocytes (Figures 4a-c) . In addition, perilipin staining of mammary glands at 72 h of involution highlights the delayed reappearance of the adipocytes in the ctsl À / À glands when compared with the controls (Figure 4d ).
Discussion
Of the three subunits encoded by the pi3kr1 gene, p85a has been implicated in a plethora of functions, which may be either PI3K dependent or independent and are exerted mainly through interaction with several binding partners in different contexts. 18 The role of the smaller p55a/p50a subunits is, however, still obscure. The only clearly defined function for p55a/p50a was revealed by their genetic deletion, which resulted in increased insulin sensitivity, demonstrating a role for the small subunits in insulin signaling, particularly in glucose and lipid metabolism. 6 It has been hypothesized that their unique N-termini may target these subunits to different compartments of the cell, thus allowing for localized PI3K-dependent signaling events. For example, the p55a N-terminus has been shown to interact with tubulin, thus localizing this subunit to the microtubule network. 7 Here we show that p55a/p50a, specifically upregulated at the onset of involution by Stat3, have a fundamental role in vivo by regulating mammary gland involution. In the absence of the small subunits, mammary gland involution is substantially delayed, with a severe effect on the levels of cell death during the early stages of this process (Figure 1) . Surprisingly, p55a/p50a affect cell death independently of PI3K signaling, as phosphorylation of Akt and its downstream targets are largely unaffected in knockout tissue (Supplementary Figure 1) .
One mechanism by which the subunits influence cell death, which occurs by LM-PCD, is by upregulating levels of the lysosomal protease cathepsin L (Figure 2 ). Furthermore, we provide evidence that reduced activity of cathepsin L can at least partially account for the delay in involution observed in the p55a/p50a mice, as complete depletion of this lysosomal protease, as observed in ctsl À / À mice, is sufficient to delay mammary gland involution (Figure 4 ).
The upregulation of cathepsin L does not seem to occur directly through transcriptional regulation, as the mRNA levels of cathepsin L are not significantly reduced in the p55a À / À / p50a À / À mice (Figure 3d ). Post-transcriptional regulation of cathepsin L has not been investigated and could occur by alterations in mRNA stability or post-translational delivery to the lysosomal compartment.
Interestingly, however, we could detect p55a/p50a, as well as p85a, in the nuclear compartment of mammary tissue and mammary cell lines (Figures 3a and b) . There is some evidence in the literature for nuclear localization of particular regulatory subunits of PI3K. For example, p85a has been shown to localize to the nuclei of both PC12 cells upon Haloperidol treatment 16 and C6 glial cells cultured in serum-free medium. 17 More recently, interaction of p85a or p85b with XBP-1s has been shown to increase nuclear localization of XBP-1s and transcriptional regulation of the UPR. 4, 5 Furthermore, both p85a and p85b have been shown to be present in nuclear preparations of mouse embryonic fibroblasts. 4 Our finding that p55a/p50a localize to the nuclei of mammary cells and associate with chromatin is the first demonstration of a potential nuclear function for these smaller subunits. This notion is supported by our microarray analysis demonstrating that gene expression during involution is modulated by depletion of p55a/p50a suggesting a role in transcriptional regulation, which could be mediated by influencing the activity of other transcription factors, such as Stat3 (Figure 3c and Supplementary Tables). However, further investigation is required to address the specific mechanism.
Mammary gland involution is associated with a marked upregulation of the APR and inflammatory genes. 11, 14, 19 The APR is a component of the innate immune system and the first mechanism of defense against disease, aimed at minimizing tissue damage while promoting repair. We have recently demonstrated some of the APR genes to be transcriptional targets of Stat3 in the mammary gland, 10 where they may act to ensure efficient tissue remodeling.
An initial comparison of the most markedly p55a/p50a-regulated genes reveals that many downregulated targets are also substantially downregulated in the absence of Stat3. Similarly, many of the genes upregulated in the 24 h p55a/p50a-depleted mammary gland are also upregulated in the Stat3 Table 3 ). These correlations indicate that a set of Stat3-regulated involution target genes are also regulated via p55a/p50a, suggesting that these subunits modulate the Stat3 signal. Intriguingly, however, a small number of genes are upregulated in the p55a À / À /p50a
but downregulated in the Stat3 À / À glands, indicating positive Our previous work demonstrated that Stat3 regulates LM-PCD 12 and induces expression of p55a and p50a. 13 In other work (Pensa et al., unpublished), we have shown that We propose a novel function for these subunits as key factors in determining the balance of tissue remodeling signals and cell death in the physiological context of mammary gland involution. This balance between autophagy and cell death is of crucial importance in many different biological processes. Thus, we anticipate that p55a/p50a may be central in cell fate decisions in other systems in vivo where they can regulate autophagy and cell death. The APR and the inflammatory response associated with involution have been recently demonstrated to provide a pro-tumorigenic microenvironment in the mammary gland. 20 In addition, deregulation of Stat3 target genes can account for its pro-tumorigenic role as opposed to the pro-cell death role in normal tissue. 21 It would be interesting to investigate if the subunits could be responsible for such a switch in Stat3 function in pathological versus physiological conditions. The observation that p55a/p50a show higher levels in low grade as compared with aggressive neuroblastomas 22 and that transcription of p55a/p50a by Stat3 switches MEFs from a pro-survival to an anti-survival response to leukemia inhibitory factor (LIF) 23 would support this hypothesis.
Materials and Methods
Animal husbandry. p55a/p50a and ctsl null mice have been generated previously (Chen et al. 6 and Roth et al., 24 respectively). C57BL/6 mice were purchased from Harlan Labs (Indianapolis, IN, USA) . The mice were bred in regular cages with food and water ad libitum. Virgin female mice, 8-14 weeks old, were mated and males were subsequently removed before birth to avoid second pregnancies. Dams were killed at indicated time points. For involution studies, pups were removed at 10 days of lactation. Unless otherwise stated, at least three mice were used for each time point in every experiment. All animals were treated according to local ethical committee and the UK Home Office guidelines and killed through CO 2 asphyxiation or dislocation of the neck.
Assessment of delayed involution in vivo.
To quantify the delay of mammary gland involution, the area occupied by adipocytes was assessed by analysis of hematoxylin-and eosin-stained mammary gland sections using ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA).
Hematoxylin and eosin staining. Hematoxylin and eosin staining was carried out as previously described. 25 Adipocyte isolation. Pairs of cervical and abdominal (minus lymph nodes) glands were extracted, pooled and minced manually and a small amount of tissue was retained for extraction of total protein. The remaining material was digested for 1 h in 2.5 ml 3 mg/ml type II collagenase at 37 1C with shaking (200 r.p.m.), followed by filtration (filter cap 100 mm pore size; BD Biosciences, San Jose, CA, USA) and centrifugation at low speed (1300 r.p.m.). After centrifugation, mature adipocytes on the surface of the digestion mixture were removed by pipette. 'Undigested' tissue (material that failed to pass through the filter mesh) containing epithelium, stroma and some undigested fat, was retained for analysis. Pelleted material (1300 r.p.m.), expected to contain pre-adipocytes, was also similarly retained.
Lysosomal subcellular fractionation. Lysosomal crude extracts were obtained as previously described. 3 Briefly, lymph node divested number four glands were homogenized in a tight-fitting handheld homogenizer in 1 ml of subcellular fractionation buffer (HEPES-KOH 20 mM, sucrose 250 mM, KCl 10 mM, MgCl 2 1.5 mM, EDTA 1 mM, EGTA 1 mM, dithiothreitol 8 mM, Pefabloc 1 mM (Sigma Aldrich, St. Louis, MO, USA), at pH 7.5). Debris and nuclei were pelleted at 750 g (3500 r.p.m., Optima L-100 XP Ultracentrifuge, 4 1C, BeckmanCoulter, Brea, CA, USA) for 12 min. The supernatant was spun at 10 000 g (12 900 r.p.m.) for 35 min to pellet lysosomes and other organelles. The pellet was rinsed and collected in 300 ml subcellular fractionation buffer as lysosomal fraction. The supernatant, containing cytosolic and extracellular components, was cleared of microsomes by an additional spin at 100 000 g (40 000 r.p.m.) for 1 h and collected as cytosolic fraction. Three cycles of freezing and thawing were used to disrupt the organelles.
Cathepsins B and L activity. To measure lysosomal and cytosolic cathepsin activity, subcellular fractionation was carried out as described earlier.
Protein levels were assessed with the BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA, USA) and equal amounts of protein (4 mg) were added to a total of 200 ml cathepsin reaction buffer (sodium acetate 50 mM, EDTA 8 mM, dithiothreitol 8 mM and Pefabloc subcellular fractionation buffer 1 mM, at pH 6). Cathepsin B þ L activity was measured after incubation (15 min, 37 1C) with the fluorescent substrate Z-Phe-Arg-AMC (50 mM; Merk Millipore, Darmstadt, Germany) in a Synergy HT Multi-Detection Microplate Reader (excitation 380 nM, emission 442 nM; Bio-TEK, Winooski, VT, USA). In parallel, a sample with added cathepsin B inhibitor CA-074 (5 mM; Peptanova, Sandhausen, Germany) was measured to determine cathepsin L activity. The cathepsin B activity measurement was detracted from the difference between readings.
Cytosolic-nuclear fractionation. Cytosolic and nuclear fractions were prepared as following: frozen tissue powder was resuspended in three pellet volumes of cold buffer A (20 mM HEPES, pH 7.0, 0.15 mM EDTA, 0.015 mM EGTA, 10 mM KCl, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% Nonidet P-40, and protease inhibitors cocktail (Sigma Aldrich)). The homogenate was centrifuged at 500 Â g for 5 min. The supernatant corresponds to the cytosolic fraction. The nuclear pellet was resuspended in five pellet volumes of cold buffer B (10 mM HEPES, pH 8.0, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 25% glycerol, 0.1 M NaCl and protease inhibitors cocktail). After centrifugation, the nuclei were resuspended in two pellet volumes of hypertonic cold buffer C (10 mM HEPES, pH 8.0, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 25% glycerol, 0.4 M NaCl and protease inhibitors cocktail) and were incubated for 30 min at 4 1C in a rotating wheel and nuclear debris were removed by centrifugation at 900 Â g for 20 min at 4 1C.
Small-scale chromatin-cytosolic fractionation. EpH4 cells were grown in DMEM (Life Technologies, Carlsbad, CA, USA) containing 10% fetal calf serum (Sigma Aldrich). To isolate the chromatin, cells were plated in 10 cm dishes, treated with OSM for 24 h, crosslinked and quenched as described before. 26 Cells were washed with PBS, centrifuged and the cell pellet was resuspended in buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM dithiothreitol and protease inhibitor cocktail (Sigma Aldrich)). Triton X-100 was added (0.1% final concentration), the cells were incubated on ice for 10 min, and nuclei were collected by centrifugation (5 min, 1300 Â g, 4 1C). The supernatant constitutes the cytosolic fraction. The nuclei were washed once in buffer A and lysed for 30 min in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol and protease inhibitor cocktail), and insoluble chromatin and soluble fraction were separated by centrifugation (5 min, 1700 Â g, 4 1C). The chromatin fraction was washed five times with buffer B. On the last wash, sonication was performed for 30 s. After centrifugation at 4000 r.p.m. for 5 min at 4 1C, the chromatin pellet was resuspended in 55 ml 1X DNase I Buffer þ 5 ml DNase (Promega, Madison, WI, USA), incubated at 37 1C for 30-60 min and boiled 15 min in sodium dodecyl sulfate loading buffer.
Quantitative real-time PCR. RNA extraction, complementary DNA synthesis and quantitative real-time PCR were carried out as previously described. Immunoblotting. Sample preparation and immunoblotting were carried out as previously described. 25 The following antibodies from Cell Signalling Technologies (Danvers, MA, USA) were used: anti-phospho-Stat3 (Tyr705: 9131), anti-total-Stat3 (9132), anti-phospho-Akt (Ser473: 9271), anti-total-Akt (9272), antiphospho-Gsk3b (9331), anti-GSK3b (9315), anti-Akt1 (2967), anti-Akt2 (2964), anti-Akt3 (4059) and anti-lamin A/C (2032). The following antibodies from Abcam (Cambridge, UK) were used: anti-cathepsin B (ab33538), anti-Lamp2 (ab13524), anti-tubulin (ab6160) and anti-b-actin (ab8227). The following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used: anti-C/ebpa (sc-61), anti-histone H3 (sc8654), anti-Bax (sc-7480), anti-Bcl-2 (sc7382) and anti-Bcl-xL (sc-634). Other commercial antibodies used were: anti-cathepsin L (MAB9521), anti-cathepsin L (AF1515, used for the immunodetection of cathepsin L in the cathepsin L knockout and control glands) and anti-Bid (MB860) from R&D Systems (Minneapolis, MN, USA), anti-pan-p85 (Merk Millipore, 06-496, also detects p50a/p55a subunits), anti-cytochrome c (65981A) and anti-E-cadherin (610182) from BD Biosciences. All antibodies were used at a standard dilution of 1 : 1,000. Secondary horseradish peroxidase-conjugated antibodies were purchased from Dako (Glostrup, Denmark).
Immunohistochemistry. Tissue sections were prepared as previously described. 25 For assessment of cathepsin localization on tissue sections, the tissue was permeabilized with 0.1% saponin (Sigma Aldrich) in PBS and blocked in 10% normal goat serum (Dako) in PBS, 0.01% saponin. The pictures of c-C3 were acquired on a Zeiss Axioplan 2 microscope (Zeiss, Jena, Germany). All the other pictures were acquired on a Zeiss LSM 700 confocal microscope. Z-stacks for the cathepsins B and L costaining were carried out on at least five z-stacks from two independent biological replicates with at least 10 cross-sections for every sample. Primary antibodies used were: rat anti-cathepsin L (R&D Systems; MAB9521, 1 : 200), rabbit anti-cathepsin B (Abcam; 1 : 100), mouse anti-Ecadherin (BD Biosciences; 610182, 1 : 500), rabbit anti-perilipin (Cell Signalling Technologies; 3470, 1 : 200) and rabbit anti-cleaved caspase 3 (Cell Signalling Technologies; 9661, 1 : 100). Secondary antibodies used were Alexa Fluor 488 goat-anti-rabbit-IgG (Life Technologies; 1 : 500) Cy3 goat-anti-rabbit (Life Technologies; 1 : 500) and Cy3 goat-anti-rat-IgG (Life Technologies; 1 : 500). Nuclei were counterstained with Hoechst 33342 (Sigma Aldrich; 1 : 1000).
Statistical analysis. Every experiment was carried out with at least three independent biological samples, unless otherwise stated. Where appropriate, statistical significance was assessed with Student's t-test.
